Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.…
Passage Bio (NASDAQ: PASG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.
The shares were at 3.920 USD on 20 November 2026, down 37.6% over 52 weeks. Its 52-week range is 3.295 USD to 20.00 USD: the price is 80.4% below the high and 19.0% above the low.
Its market capitalisation is 12.61M USD.
Passage Bio reports return on equity of -242.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 20.16M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 15.50 USD is 295.4% above the current price.